Opella's Essentiale Shows 2.5x Greater Liver Fat Reduction in Breakthrough EXCEL Trial for Fatty Liver Disease

Key Takeaways

• Essentiale essential phospholipids achieved 2.5 times greater liver fat reduction compared to diet and exercise alone in MASLD patients
• The EXCEL trial showed significant improvements in fatigue and glycemic control alongside liver fat reduction
• This represents the first-of-its-kind clinical evidence for essential phospholipids in treating Metabolic dysfunction-Associated Steatotic Liver Disease

---

PARIS, April 27, 2026 — Opella’s Essentiale has demonstrated significant efficacy in treating Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), commonly known as fatty liver disease, according to results from the groundbreaking EXCEL clinical trial.

Trial Results Show Superior Outcomes

The multi-center EXCEL study revealed that patients treated with essential phospholipids (Essentiale) experienced a 2.5-fold greater reduction in liver fat compared to those receiving standard diet and exercise interventions alone. Beyond liver fat reduction, participants showed marked improvements in fatigue levels and glycemic control.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Addressing a Growing Health Crisis

MASLD affects millions globally and represents one of the most common liver conditions worldwide. The disease, characterized by excess fat accumulation in the liver, often progresses silently and can lead to serious complications including cirrhosis and liver failure if left untreated.

“This first-of-its-kind study establishes essential phospholipids as a promising therapeutic approach for MASLD patients,” the research team noted. The trial’s robust design and significant results position Essentiale as a potential game-changer in fatty liver disease management.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market and Clinical Implications

The EXCEL trial results could reshape treatment paradigms for MASLD, offering healthcare providers an evidence-based option beyond lifestyle modifications. With limited pharmaceutical interventions currently available for fatty liver disease, Essentiale’s demonstrated efficacy addresses a significant unmet medical need.

The study’s comprehensive approach, measuring not only liver fat reduction but also quality-of-life indicators like fatigue and metabolic markers, provides a holistic view of treatment benefits that could influence clinical practice guidelines.

Opella, the consumer healthcare division behind Essentiale, continues to advance research in liver health, with these results potentially supporting expanded therapeutic applications for essential phospholipids in hepatic conditions.

---

Frequently Asked Questions

What is MASLD and how common is it?

MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease), formerly known as fatty liver disease, is characterized by excess fat accumulation in the liver. It affects millions globally and is one of the most prevalent liver conditions worldwide.

How does Essentiale work for fatty liver disease?

Essentiale contains essential phospholipids that help restore liver cell membrane integrity and function. The EXCEL trial showed it reduces liver fat 2.5 times more effectively than diet and exercise alone while improving fatigue and blood sugar control.

When will Essentiale be widely available for MASLD treatment?

While Essentiale is already available as a liver health supplement in many markets, these EXCEL trial results may support expanded therapeutic claims and broader clinical adoption. Regulatory timelines will depend on submission strategies in different regions.

Related coverage

• Federal Court Litigation on Reproductive Health: Rare Disease Implications
• European Cancer Guidelines Add Delcath Liver Therapy for Eye Melanoma
• New EU Template for Clinical Trial Recruitment and Informed Consent: What Pharma Teams Need to Know